Observing Side Effects of ATGALG Treatment in Patients with Aplastic Anemia

What this Trial Is About

Researchers are observing patients with aplastic anemia who are undergoing treatment with ATG Anti-Thymocyte Globulin or ALG Anti-Lymphocyte Globulin to better understand the clinical characteristics of any adverse reactions they experience. This observational cohort study aims to provide detailed data that can help develop better management strategies for these side effects. The study plans to enroll 200 participants who are receiving this treatment for the first time. Participants will receive ATG or ALG treatments following standard clinical guidelines. During the infusion period, typically from day 1 to day 6, researchers will monitor for infusion reactions and assess their severity. They will also track liver and kidney function damage during and up to four weeks after treatment. Additionally, the study will evaluate the occurrence and severity of serum sickness within four weeks following the infusion. Throughout the study, participants will be closely observed to record the type, severity, duration, and any necessary interventions for adverse reactions. Researchers will collect detailed data on infusion reactions, organ function, and serum sickness to understand the treatments impact better. The overall goal is to gather comprehensive information that can inform future care and safety measures for patients receiving ATGALG therapy. The study will continue until December 31, 2027.

Adverse Effects of ATG/ALG Therapy in Aplastic Anemia